Matthew D. Galsky, MD

Matthew D. Galsky, MD, Director of Genitourinary Medical Oncology, Tisch Cancer Institute

Articles by Matthew D. Galsky, MD

Peter O'Donnell, MDRoundtable | November 17, 2023
The panel shares their hopes for the future of bladder cancer treatment.
View More
Peter O'Donnell, MDRoundtable | November 17, 2023
The panel shares tips for community oncologists who may not be familiar with treating patients with EV/pembro.
Peter O'Donnell, MDRoundtable | November 17, 2023
The panel shares treatment sequencing decisions based on a few patient scenarios.
Peter O'Donnell, MDRoundtable | November 17, 2023
The panel discussed the double antibody-drug conjugate trial that assessed sacituzumab govitecan plus EV.
Peter O'Donnell, MDRoundtable | November 17, 2023
The panel shares lessons learned from the phase THOR study.
Peter O'Donnell, MDRoundtable | November 17, 2023
The panel discusses the CheckMate 901 study results.
Peter O'Donnell, MDRoundtable | November 17, 2023
The panel discussed how the EV-302 data compare to the previous JAVELIN paradigm.
Peter O'Donnell, MDRoundtable | November 17, 2023
The panel discusses the "buzz" around the EV-302 study.
Peter O'Donnell, MDRoundtable | November 13, 2023
The panel discussed continued unmet needs and challenges for patients with urothelial cancer.
Matthew D. Galsky, MDThe Uromigos | September 7, 2023
Matt Galsky continues his discussion on ctDNA in bladder cancer and covers topics such as candidate versus panel approaches.
Matthew D. Galsky, MDASCO GU Symposium 2023 | February 17, 2023
Matthew Galsky, MD, contextualizes HCRN GU 16-257 as a potential game-changer for bladder sparing in patients with MIBC.